Free Trial

Geron (GERN) Competitors

Geron logo
$1.27 +0.07 (+5.83%)
Closing price 10/20/2025 04:00 PM Eastern
Extended Trading
$1.28 +0.01 (+0.79%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GERN vs. ALKS, FOLD, CLDX, MNKD, BCRX, NVAX, OPK, DVAX, INVA, and ZBIO

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

Geron vs. Its Competitors

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Geron presently has a consensus price target of $3.79, suggesting a potential upside of 198.09%. Alkermes has a consensus price target of $42.00, suggesting a potential upside of 35.57%. Given Geron's higher probable upside, equities analysts clearly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Alkermes
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.93

Alkermes has a net margin of 23.15% compared to Geron's net margin of -53.52%. Alkermes' return on equity of 24.86% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-53.52% -31.37% -16.01%
Alkermes 23.15%24.86%17.14%

73.7% of Geron shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 7.4% of Geron shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$164.45M4.93-$174.57M-$0.13-9.77
Alkermes$1.51B3.40$367.07M$2.0814.89

Geron has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

In the previous week, Alkermes had 7 more articles in the media than Geron. MarketBeat recorded 12 mentions for Alkermes and 5 mentions for Geron. Alkermes' average media sentiment score of 0.74 beat Geron's score of 0.28 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alkermes beats Geron on 13 of the 17 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$810.28M$3.45B$6.13B$10.54B
Dividend YieldN/A2.27%5.72%4.85%
P/E Ratio-9.7723.3929.4827.34
Price / Sales4.93275.40504.70200.95
Price / CashN/A45.2825.8230.35
Price / Book2.7610.6112.616.69
Net Income-$174.57M-$52.56M$3.32B$276.46M
7 Day Performance2.42%3.95%1.88%-0.08%
1 Month Performance-3.79%16.10%8.86%3.93%
1 Year Performance-67.85%15.08%65.57%33.89%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
2.7915 of 5 stars
$1.27
+5.8%
$3.79
+198.1%
-68.9%$810.28M$164.45M-9.7770
ALKS
Alkermes
4.641 of 5 stars
$31.38
-0.4%
$42.00
+33.8%
+9.6%$5.20B$1.56B15.091,800Upcoming Earnings
FOLD
Amicus Therapeutics
4.4292 of 5 stars
$8.27
+0.1%
$15.78
+90.8%
-29.1%$2.55B$528.29M-68.91480Analyst Downgrade
CLDX
Celldex Therapeutics
1.571 of 5 stars
$27.54
+1.1%
$46.13
+67.5%
-2.1%$1.81B$7.02M-9.15150Analyst Forecast
MNKD
MannKind
3.3999 of 5 stars
$5.14
-5.5%
$11.17
+117.3%
-16.8%$1.67B$301.74M46.73400Positive News
Analyst Forecast
High Trading Volume
BCRX
BioCryst Pharmaceuticals
4.3991 of 5 stars
$7.25
-0.4%
$16.30
+124.8%
-9.1%$1.53B$450.71M-40.28530
NVAX
Novavax
3.8933 of 5 stars
$8.59
-3.5%
$14.29
+66.3%
-13.7%$1.45B$682.16M3.771,990
OPK
OPKO Health
4.0747 of 5 stars
$1.56
+0.6%
$2.63
+68.3%
+4.1%$1.23B$713.10M-6.242,997
DVAX
Dynavax Technologies
4.3339 of 5 stars
$10.35
+1.7%
$24.33
+135.1%
-8.1%$1.19B$277.25M-22.50350
INVA
Innoviva
4.3437 of 5 stars
$17.45
+0.5%
$37.60
+115.5%
-14.1%$1.09B$358.71M56.29100
ZBIO
Zenas BioPharma
2.3517 of 5 stars
$27.76
+7.2%
$38.33
+38.1%
N/A$1.09B$15M-7.82N/AHigh Trading Volume

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners